Interindividual variation in relative CYP1A2/3A4 phenotype influences susceptibility of clozapine oxidation to cytochrome P450-specific inhibition in human hepatic microsomes

Drug Metabolism and Disposition

Volumn 36, Issue 12, 2008, Pages 2547-2555

  Zhang, Wei V ^a   D'Esposito, Fabrizio ^a   Edwards, Robert J ^b   Ramzan, Iqbal ^a   Murray, Michael ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYDAMINE; CLOZAPINE; CLOZAPINE N OXIDE; CYTOCHROME P450 1A2; CYTOCHROME P450 3A4; DEXTROMETHORPHAN; FLUVOXAMINE; KETOCONAZOLE; NORCLOZAPINE; QUINIDINE; TESTOSTERONE; TOLBUTAMIDE; TRANYLCYPROMINE;

ARTICLE; CONTROLLED STUDY; DEMETHYLATION; DNA EXTRACTION; DRUG HYDROXYLATION; DRUG OXIDATION; DRUG TRANSFORMATION; ENZYME ACTIVITY; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; INDIVIDUALIZATION; LIVER MICROSOME; MICHAELIS MENTEN KINETICS; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ALLELES; ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; CATALYSIS; CLOZAPINE; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DEXTROMETHORPHAN; ENZYME INHIBITORS; FLUVOXAMINE; HUMANS; ISOENZYMES; KETOCONAZOLE; KINETICS; MICROSOMES, LIVER; OXIDATION-REDUCTION; OXIDOREDUCTASES, N-DEMETHYLATING; OXYGENASES; RECOMBINANT PROTEINS; TESTOSTERONE; TOLBUTAMIDE;

EID: 57349196359     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.023671     Document Type: Article

References (38)

1. Centorrino F, Baldessarini RJ, Frankenburg FR, Kando J, Volpicelli SA, and Flood JG (1996) Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors. Am J Psychiatry 153:820-822.
2. Centorrino F, Baldessarini RJ, Kando J, Frankenburg FR, Volpicelli SA, Puopolo PR, and Flood JG (1994) Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate. Am J Psychiatry 151:123-125.
3. Chevalier D, Cauffiez C, Allorge D, Lo-Guidice JM, Lhermitte M, Lafitte JJ, and Broly F (2001) Five novel natural allelic variants - 951A > C, 1042G > A (D348N), 1156A > T (I386F), 1217G > A (C406Y) and 1291C > T (C431Y) - of the human CYP1A2 gene in a French Caucasian population. Hum Mutat 17:355-356.
4. Cohen LG, Chesley S, Eugenio L, Flood JG, Fisch J, and Goff DC (1996) Erythromycin-induced clozapine toxic reaction. Arch Intern Med 156:675-677.
5. Dai D, Tang J, Rose R, Hodgson E, Bienstock RJ, Mohrenweiser HW, and Goldstein JA (2001) Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther 299:825-831.
6. Diaz FJ, Santoro V, Spina E, Cogollo M, Rivera TE, Botts S, and de Leon J (2008) Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables. Pharmacopsychiatry 41:81-91.
7. Edge SC, Markowitz JS, and Devane CL (1997) Clozapine drug-drug interactions: a review of the literature. Hum Psychopharmacol 12:5-20.
8. Edwards RJ, Adams DA, Watts PS, Davies DS, and Boobis AR (1998) Development of a comprehensive panel of antibodies against the major xenobiotic metabolising forms of cytochrome P450 in humans. Biochem Pharmacol 56:377-387.
9. Eiermann B, Engel G, Johansson I, Zanger UM, and Bertilsson L (1997) The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br J Clin Pharmacol 44:439-446.
10. Eiselt R, Domanski TL, Zibat A, Mueller R, Presecan-Siedel E, Hustert E, Zanger UM, Brockmoller J, Klenk HP, Meyer UA, et al. (2001) Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics 11:447-458.
11. Funderburg L, Vertrees J. True J, and Miller A (1994) Seizure following addition of erythromycin to clozapine therapy. Am J Psychiatry 151:1840-1841.
12. Gerson SL, Arce C, and Meltzer HY (1994) N-Desmethylclozapine: a clozapine metabolite that suppresses haemopoiesis. Br J Haematol 86:555-561.
13. Hägg S, Spigset O, Mjörndal T, Granberg K, Persbo-Lundqvist G, and Dahlqvist R (1999) Absence of interaction between erythromycin and a single dose of clozapine. Eur J Clin Pharmacol 55:221-226.
14. Hiemke C, Weigmann H, Härtter S, Dahmen N, Wetzel H, and Müller H (1994) Elevated levels of clozapine in serum after addition of fluvoxamine. J Clin Psychopharmacol 14:279-281.
15. Jerling M, Lindström L, Bondesson U, and Bertilsson L (1994) Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 16:368-374.
16. Jiang Z, Dragin N, Jorge-Nebert LF, Martin MV, Guengerich FP, Aklillu E, Ingelman-Sundberg M, Hammons GJ, Lyn-Cook BD, Kadlubar FF, et al. (2006) Search for an association between the human CYP1A2 genotype and CYP1A2 metabolic phenotype. Pharmacogenet Genomics 16:359-367.
17. Knodell RG, Hall SD, Wilkinson GR, and Guengerich FP (1987) Hepatic metabolism of tolbutamide: characterization of the form of cytochrome P450 involved in methyl hydroxylation and relationship to in vivo disposition. J Pharmacol Exp Ther 241:1112-1119.
18. Kontaxakis VP, Ferentinos PP, Havaki-Kontaxaki BJ, Paplos KG, Roukas DK, and Christodoulou GN (2005) Case studies of adjunctive agents in clozapine-resistant schizophrenic patients. Clin Neuropharmacol 28:50-53.
19. Laemmli UK (1970) Cleavage of structural proteins during assembly of the head of bacteriophage T4. Nature 227:680-685.
20. Linnet K and Olesen OV (1997) Metabolism of clozapine by cDNA-expressed human cytochrome P450 enzymes. Drug Metab Dispos 25:1379-1382.
21. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 93:265-275.
22. Murray M (1992) Metabolite intermediate complexation of microsomal cytochrome P450 2C11 in male rat liver by nortriptyline. Mol Pharmacol 42:931-938.
23. Murray M, Zaluzny L, and Farrell GC (1986) Drug metabolism in cirrhosis: selective changes in cytochrome P-450 isozymes in the choline-deficient rat model. Biochem Pharmacol 35:1817-1824.
24. Ozdemir V, Kalow W, Okey AB, Lam MS, Albers LJ, Reist C, Fourie J, Posner P, Collins EJ, and Roy R (2001) Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and the C > A polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamine. J Clin Psychopharmacol 21:603-607.
25. Pirmohamed M, Williams D, Madden S, Templeton E, and Park BK (1995) Metabolism and bioactivation of clozapine by human liver in vitro. J Pharmacol Exp Ther 272:984-990.
26. Prough RA, Burke MD, and Mayer RT (1978) Direct fluorometric methods for measuring mixed function oxidase activity. Methods Enzymol 52:372-377.
27. Raaska K and Neuvonen PJ (1998) Serum concentrations of clozapine and N-desmethylclozapine are unaffected by the potent CYP3A4 inhibitor itraconazole. Eur J Clin Pharmacol 54:167-170.
28. Raaska K and Neuvonen PJ (2000) Ciprofloxacin increases serum clozapine and N-desmethylclozapine: a study in patients with schizophrenia. Eur J Clin Pharmacol 56:585-589.
29. Sata F, Sapone A, Elizondo G, Stocker P, Miller VP, Zheng W, Raunio H, Crespi CL, and Gonzalez FJ (2000) CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin Pharmacol Ther 67:48-56.
30. Taylor D, Bodani M, Hubbeling A, and Murray R (1999) The effect of nefazodone on clozapine plasma concentrations. Int Clin Psychopharmacol 14:185-187.
31. Towbin H, Staehelin T, and Gordon J (1979) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A 76:4350-4354.
32. Tugnait M, Hawes EM, McKay G, Eichelbaum M, and Midha KK (1999) Characterization of the human hepatic cytochromes P450 involved in the in vitro oxidation of clozapine. Chem Biol Interact 118:171-189.
33. Tugnait M, Hawes EM, McKay G, Rettie AE, Haining RL, and Midha KK (1997) N-Oxygenation of clozapine by flavin-containing monooxygenase. Drug Metab Dispos 25:524-527.
34. Vielnascher E, Spatzenegger M, Mayrhofer A, Klinger P, and Jäger W (1996) Metabolism of dextromethorphan in human liver microsomes: a rapid HPLC assay to monitor cytochrome P450 2D6 activity. Pharmazie 51:586-588.
35. Wang CY, Zhang ZJ, Li WB, Zhai YM, Cai ZJ, Weng YZ, Zhu RH, Zhao JP, and Zhou HH (2004) The differential effects of steady-state fluvoxamine on the pharmacokinetics of olanzapine and clozapine in healthy volunteers. J Clin Pharmacol 44:785-792.
36. Wetzel H, Anghelescu I, Szegedi A, Wiesner J, Weigmann H, Härter S, and Hiemke C (1998) Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study. J Clin Psychopharmacol 18:2-9.
37. Zhang WV, Ramzan I, and Murray M (2007) Impaired microsomal oxidation of the atypical antipsychotic agent clozapine in hepatic steatosis. J Pharmacol Exp Ther 322:770-777.
38. Zhou H, Josephy PD, Kim D, and Guengerich FP (2004) Functional characterization of four allelic variants of human cytochrome P450 1A2. Arch Biochem Biophys 422:23-30.